CrossBridge Bio acquired by Eli Lilly
Eli Lilly agreed to acquire CrossBridge Bio, a therapeutics brand, on Apr 14, 2026.
Preliminary: The announcement date, value basis and value notes are not yet independently verified.
Transaction summary
- Target
- CrossBridge Bio
- Acquirer
- Eli Lilly
- Seller
- -
- Announced
- 2026-04-14(unverified)
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-07-13
- Latest update
- 2026-10-29
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed | USD
Basis: Undisclosed
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Enterprise value is unavailable.
Source summary
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates - Business Wire
ConfirmedBusiness Wire reported that CrossBridge Bio entered an agreement to be acquired by Eli Lilly to advance next-generation dual-payload antibody-drug conjugates.
Open sourceContinue your research
Related transaction comps
AtaiBeckley acquired by Eli Lilly and Company
2026-09-11 · Confirmed
View transaction → Same buyer / investor4E Therapeutics acquired by Eli Lilly and Company
2026-06-16 · Confirmed
View transaction → Same buyer / investorKelonia Therapeutics acquired by Eli Lilly and Company
2026-04-20 · Confirmed
View transaction → Antibody-Drug ConjugatesTubulis acquired by Gilead Sciences
2026-05-21 · Confirmed
View transaction →